Arbutin effectively ameliorates the symptoms of Parkinson’s disease: the role of adenosine receptors and cyclic adenosine monophosphate

Abstract
An antagonistic communication exists between adenosinergic and dopaminergic signaling in the basal ganglia, which suggests that the suppression of adenosine A2A receptors-cyclic adenosine monophosphate pathway may be able to restore the disrupted dopamine transmission that results in motor symptoms in Parkinson’s disease (PD). Arbutin is a natural glycoside that possesses antioxidant, anti-inflammatory, and neuroprotective properties. The purpose of this study was to investigate whether arbutin could ameliorate the symptoms of PD and to examine the underlying mechanism. In this study, Swiss albino mouse models of PD were established by the intraperitoneal injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for 4 successive days, with the concurrent intraperitoneal administration of arbutin (50 and 100 mg/kg) for 7 days. The results showed that arbutin significantly reduced lipid peroxidation, total nitrite levels, and inflammation in the substantia nigra and striatum of PD mouse models. In addition, arbutin decreased the activity of endogenous antioxidants, reduced the levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and γ-aminobutyric acid, and minimized neurodegeneration in the striatum. Arbutin also reduced the abnormal performance of PD mouse models in the open field test, bar test, pole test, and rotarod test. The therapeutic efficacy of arbutin was similar to that of madopar. The intraperitoneal injection of the A2AR agonist CGS21680 (0.5 mg/kg) attenuated the therapeutic effects of arbutin, whereas the intraperitoneal injection of forskolin (3 mg/kg) enhanced arbutin-mediated improvements. These findings suggest that arbutin can improve the performance of PD mouse models by inhibiting the function of the A2AR and enhancing the effects of cyclic adenosine monophosphate. This study was approved by the Institutional Animal Ethics Committee (1616/ PO/Re/S/12/CPCSEA) on November 17, 2019 (approval No. IAEC/2019/010).

Key Words: arbutin; CGS21680; dopamine; forskolin; GABA; inflammation; oxidative stress; Parkinson’s disease; striatum; substantia nigra

Introduction
Parkinson’s disease (PD) is the second-most frequent progressive neurodegenerative disorder, affecting 1–3% of individuals older than 65 years. PD has a higher prevalence in males than in females (Hirsch et al., 2016). Although sporadic PD is more prevalent than familial PD (10%), both forms share common features, such as the intraneuronal accumulation of α-synuclein and ubiquitin in intracytoplasmic inclusions called Lewy bodies (Meredith et al., 2008; Bei et al., 2019). Reduced dopaminergic neuron density in the substantia nigra (SN) pars compacta leads to a dopamine deficit in the basal ganglia, which results in the typical clinical symptoms of PD (Sveinbjornsdottir, 2016). The degeneration of approximately 70% of the dopaminergic neurons in the SN pars compacta...
results in the development of motor symptoms, such as bradykinesia, rigidity, tremor, balance deficiencies, posture instability, and gait defects in PD (Hartmann, 2004). Non-motor symptoms, which may appear long before motor symptoms, include constipation, sleep disturbances (e.g., hyposmia and rapid eye movement), urinary incontinence, hallucinations, dementia, and hypotension (Radhakrishnan and Goyal, 2018; Seguella et al., 2020).

The current arsenal available for PD pharmacotherapy includes several drugs (e.g., levodopa/carbidopa, selegiline, and bromocriptine), which exclusively target the dopaminergic pathway for the symptomatic treatment of motor dysfunction, with limited long-term benefits and associated with a variety of adverse effects, such as dyskinesia, motor fluctuations, and psychosis (Abeliovich and Gitler, 2016). Several drugs are currently being examined in clinical trials: safinamide (NCT03881371), exenatide (NCT04232963), and ganoderma (NCT03594656) are in phase 3 trials; liraglutide (NCT02953665), cannabidiol (NCT03582137), bumetanide (NCT03899324), and nicotine (NCT03865121) are in phase 2 trials; and lithium (NCT04273932), rifaximin (NCT03575195), and flumazenil (NCT03462641) are in phase 1 trials. These drugs have been suggested to be able to improve the standard of living for PD patients (McFarthing et al., 2020). The pathogenesis of PD is multifaceted; however, none of the currently used therapeutic approaches are effective for the prevention of PD symptom relapse or are able to reverse or prevent the underlying neurodegenerative progression of the disease (Ravina et al., 2003). Therefore, a shift in focus toward the non-dopaminergic receptor and pharmacotherapies has occurred during recent years. The inhibition of the adenosine A2A receptors (A2ARs) and dopamine D2 receptors (D2Rs) in the striatum (ST) allows for antagonistic communications between adenosinergic and dopaminergic signaling (Kulisevsky and Poyurovsky, 2012). Evidence has suggested that the concomitant activation of D2 receptors and the inhibition of A2ARs can substantially improve the motor functions in PD patients (Shen and Chen, 2009). Subsequently, computational strategies have been used to develop dual/multiple target ligands that act on heterodimeric A2AR/D2 receptor complexes (Shao et al., 2018), adenosine A2A receptor (A2AR) and dopamine D2 receptor (D2R) in an MPTP-induced PD mouse model, in association with the effects of intermittent L-DOPA/carbidopa therapy and reduction of “off” phases in PD patients. (Mao et al., 2020). In PD patients, “off” episodes are characterized by the worsening of motor and non-motor symptoms, despite continued L-DOPA therapy. The upregulation of A2ARs in response to L-DOPA/carbidopa therapy and the subsequent activation of the indirect pathway in the basal ganglia decreases motor activation, precipitating these “off” episodes (Berger et al., 2020). A2AR antagonists, such as istradefylline, can abolish the adenosinergic effects of intermittent L-DOPA/carbidopa therapy and reduce the occurrence of “off” phases in PD patients.

Arbutin (4-hydroxyphenyl-β-D-glucopyranoside, Figure 1) is a hydroquinone that is widely found in several plant families, such as Lamiaceae, Ericaceae, Rosaceae, and Saxifragaceae (Pop et al., 2009). Arbutin suppresses various enzymatic activities, such as tyrosinase, α-amylase, and α-glucosidase, resulting in effects on melanin biosynthesis and hyperglycemia (Yousefi et al., 2013). Arbutin also inhibits the expression of genes associated with pro-inflammatory cytokines (e.g., interleukins) and free radical biosynthesis (Lee and Kim, 2012; Khadir et al., 2015). Arbutin has been associated with a variety of pharmacological activities, including anti-hypertensive, anti-diabetic, anti-seizure, anti-microbial, anti-tussive, anti-cystitis, anti-infective, diuretic, gastroprotective, hepatoprotective, and anti-hyperlipidemia activities (Myagmar et al., 2004; Shahaboddin et al., 2011; Dadgar et al., 2018; Ahmadian et al., 2019; Ye et al., 2019). Improvements in cognitive functions and motor performance following arbutin treatment have been demonstrated in pre-clinical tests in models of Alzheimer’s disease (streptozotocin), epilepsy (pentylenetetrazol), and PD (MPTP) (Dadgar et al., 2018; Ahmadian et al., 2019; Dastan et al., 2019). Furthermore, significant improvements in the motor functions of a Drosophila model of PD and the inhibition of in vitro rotenone-triggered mitochondrial dysfunction have suggested that arbutin may potentially benefit PD therapy (Ding et al., 2020). Based on the existing literature, the arbutin-mediated protection from excitotoxic (Ahmadian et al., 2019) and autophagic (via 5′ adenosine monophosphate-activated protein kinase, AMPK) (Zhang et al., 2019; Ding et al., 2020) neurodegeneration indicates a potential role for A2ARs in the pharmacodynamics of arbutin. Therefore, the present study was performed to evaluate the effects of arbutin on the behavioral impairments and biochemical parameters in an MPTP-induced PD mouse model, in association with the effects of arbutin on A2ARs and the cAMP pathway.

Material and Methods

Experimental animals and groups

All animal experimentation was performed according to the guidelines established by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India, New Delhi. Fifty-six male Swiss albino mice (body weight 25–30 g; age 8–10 weeks) were procured from National Institute of Pharmaceutical Education and Research (NIPER), Mohali (India) after the authorization of the Institutional Animal Ethics Committee (1616/PO/Re/S/12/CPCSEA) on November 17, 2019 (approval No. IAEC/2019/010). Mice were maintained in the Animal House Facility of the institute under a standard laboratory environment (temperature, 21–25 °C, humidity, 30–50%; light-dark cycle, 12 hours each). The animals were housed in cages made of polyacrylic material (size 44 × 29 × 16 cm). Mice were fed a standard rodent pellet diet, and free access to water was allowed. Mice were allowed to acclimatize to the laboratory conditions for at least two weeks before experiments were initiated (experimentation was performed from 09:00 to 18:00). The caretakers were blinded to the different drug treatments.

The mice were distributed into 8 groups, in a single-blinded manner using the random allocation method (n = 7 each group): (i) the vehicle-control group was treated with saline (5%
mL/kg body weight each day, intraperitoneal injection (i.p.); (ii) the Arbutin50 group was administered arbutin (50 mg/kg, i.p., 7 days; purity > 98%, Sigma-Aldrich, Mumbai, India); (iii) the MPTP group was administered MPTP (30 mg/kg, i.p.; Sigma-Aldrich), from days 1 to 4; (iv) the MPTP + Arbutin50 group was administered both MPTP (30 mg/kg for 4 days) and arbutin (50 mg/kg, i.p.) for 7 days; (v) the MPTP + Arbutin100 group was administered both MPTP (30 mg/kg and arbutin (100 mg/kg, i.p.); (vi) the MPTP + Madopar group was administered MPTP, and madopar (120 mg/kg, oral administration; levodopa and benserazide; Nicholas-Piramal, Mumbai, India) was administered orally, 30 minutes after MPTP injection for 7 consecutive days; (vii) the MPTP + CGS21680 + Arbutin50 group was treated with MPTP, CGS21680 (0.5 mg/kg, i.p.; Sigma-Aldrich), and arbutin (50 mg/kg, i.p.); and (viii) the MPTP + Forskolin + Arbutin50 group was treated with MPTP, forskolin (3 mg/kg, i.p.; Sigma-Aldrich), and arbutin (50 mg/kg, i.p.). Hydrochloride has a molecular weight of 35.4, which corresponds to 17% of the MPTP hydrochloride weight. Therefore, 35.1 mg/kg (20 mg/kg × 1.17) of MPTP hydrochloride was used to deliver a dose equivalent to 30 mg/kg free MPTP, according to the procedure described by Jackson-Lewis and Przedborski (1999). The quantity of MPTP necessary for the entire experiment was quantified based on the total body weight of the mice designated to receive MPTP treatment, and this quantity was dissolved in sterile saline so that each mouse was treated from the same batch. A subchronic dose (30 mg/kg per day, i.p.) of MPTP was prepared using normal saline (vehicle) and injected daily for 4 days (from day 1 to day 4, cumulative dose of 120 mg/kg). The arbutin dose was prepared by dissolving in normal saline, and arbutin was injected (Myagmar et al., 2004; Dadgar et al., 2018; Ahmadian et al., 2019; Ye et al., 2019) 30 minutes after MPTP administration for 7 consecutive days (Prema et al., 2015). The A2AR agonist CGS21680 hydrochloride (0.5 mg/kg, i.p.) and the adenylyl cyclase agonist forskolin (3 mg/kg, i.p.) were administered to separate groups of mice, 1 hour before behavioral studies were performed, to explore the roles played by adenosine receptors and CAMP in the mechanisms through which arbutin modulates PD pathology (Guzmán-Gutierrez and Navarrete, 2009; Vuaden et al., 2011). Prior to the initiation of experiments, the mice were subjected to trials on all apparatus used for the behavioral studies to optimize their performances. Behavioral evaluations, including the open field test (OFT), catalepsy test, rotarod test, and pole test, were performed on days 6 and 7, in a blinded manner. The mean scores of three performances for each experiment were quantified during the behavioral assessments (Figure 2).

**Arbutin**

\[
\text{HO} - \text{C} - \text{OH} \quad \text{HO} - \text{C} - \text{OH}
\]

\[
\text{HO} - \text{C} - \text{OH} \quad \text{HO} - \text{C} - \text{OH}
\]

**CGS-21680**

\[
\text{HO} - \text{C} - \text{OH} \quad \text{HO} - \text{C} - \text{OH}
\]

**Figure 1 | Chemical structures of arbutin and CGS21680.** Arbutin (IUPAC nomenclature: (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(4-hydroxyphenoxy)xane-3,4,5-triol) has 5 –OH groups that impart strong antioxidant properties. CGS21680 (IUPAC nomenclature: 3-[4-[[5-amino-9-[(2R,3S,4S,5R)-3,4-dihydroxyxoxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propanoic acid) is a highly selective adenosine A2A receptor agonist with an inhibition constant (K_i) of 27 nM.

**Figure 2 | Experimental design of the study.** 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was administered (50 mg/kg, i.p.) to mice for 4 days, and arbutin (50 and 100 mg/kg, i.p.) was concurrently administered for 7 days. CGS21680 (adenosine A2A receptor agonist, dose 0.5 mg/kg, i.p.) and forskolin (adenylyl cyclase agonist, dose 3 mg/kg, i.p.) were administered one hour before performing the behavioral studies, which were conducted on days 6 and 7 to assess the Parkinson’s disease-associated symptoms, such as effects on posture, movement, motor coordination, muscle strength, and rigidity. After the behavioral studies were performed, the striatum and substantia nigra regions were dissected from the brain, and biomarkers of oxidative stress, inflammation, and neurotransmitter levels were evaluated. DOPAC: 3,4-Dihydroxyphenylacetic acid; GABA: γ-aminobutyric acid; HVA: homovanillic acid; i.p.: intraperitoneal injection; NF-xb: nuclear factor kappa B; TNF-α: tumor necrosis factor-α.

The floor was divided into twenty-five 15 × 15 cm² squares, using blue lines, and a large central square (45 × 45 cm²) in the middle of the arena was defined using red lines (Brown et al., 1999). Behavior in the OFT was scored by counting the number of times each mouse performed the following: (a) the forced configuration: forced the mouse maintained this forced position, with both front paws on the horizontal wooden bar (4-cm height). The duration that the mouse maintained this forced position, with both front limbs outstretched and resting on the bar, was considered to serve as an index of cataleptic behavior. The removal of both front paws from the bar or any movement of the head in an exploratory position was considered to be the endpoint of catalepsy. The time period to the first movement of the front paws on the horizontal bar was reported as the cataleptic time (cut-off time of 180 seconds).

**Catalepsy**

Catalepsy refers to the freezing condition manifested by postural immobility (akinesia) and muscular rigidity. Cataleptic behavior was assessed using the bar test (Ferré et al., 1990). The animal was handled by its tail, with the forepaws placed on a horizontal wooden bar (4-cm height). The duration that the mouse maintained this forced position, with both front limbs outstretched and resting on the bar, was considered to serve as an index of cataleptic behavior. The removal of both front paws from the bar or any movement of the head in an exploratory position was considered to be the endpoint of catalepsy. The time period to the first movement of the front paws on the horizontal bar was reported as the cataleptic time (cut-off time of 180 seconds).

**Pole test**

The pole test is commonly used for the evaluation of bradykinesia. We used the standard method described by Ogawa et al. (1985). Briefly, each mouse was positioned head-up at the apex of a wooden pole (height: 50 cm; diameter: 1 cm), which was placed vertically in an upright position in its home cage. The inherent tendency of a mouse positioned head-up on the top of a pole is to re-align to a head-down position and then to move down the length of the pole to return to its home cage. Between each test, the OFT apparatus was thoroughly cleaned with 70% ethyl alcohol to eliminate any olfactory cues.

**Rotarod test**

The rotarod test is widely used to evaluate the muscle strength.
and motor coordination of rodents. The time that an animal remains on a rotating rod is a gauge of its overall physical state, balance, coordination, and ability to forecast motor activities. A digital rotarod apparatus (INCO, Ambala, India), consisting of 4 separate sections, allowed the examination of 4 animals simultaneously. Mice were handled by their tails and placed at the center of the rod in each compartment. The rotarod test was conducted at various speeds (5, 10, and 20 r/min), and the fall latency was determined for each mouse (Rozas et al., 1998).

**Biochemical estimations**

After behavioral testing, the mice were euthanized by cervical dislocation, and the brains were immediately isolated for biochemical analyses (n = 6). The isolated brains were rinsed with ice-cold isotonic saline, and the SN and ST were removed according to a mouse brain atlas (Kuan et al., 2015). A 10% w/v combined homogenate of the SN and ST structures was prepared in 50 mM phosphate buffer (ice-cold, pH 7.4) using a tissue homogenizer (Remi Motors, Remi-Electrotechnik, Vasai, India). The homogenized brain tissue was centrifuged (CPR-30 Remi Compufuge, Vasai, India) at 12,000 × g for 15 minutes (4°C), and the supernatant was obtained. The change in the absorbance prevents formazan production. Catalase (EC 1.11.1.6) activity in the supernatant, 1.5 mM nitroblue tetrazolium (NBT), was determined by Winterbourn et al. (1975), using ε (formazan) = 15,000 M–1cm–1 at λ_max = 532 nm (Ohkawa et al., 1979). To measure GSH, the assay mixture (final volume 3 mL), containing supernatant and 4% sulfosalicylic acid (LobaChemie), was centrifuged (2000 × g for 10 minutes at 4°C), and the supernatant was combined with 5,5′-dithiobis-(2-nitrobenzoic acid) (0.1 mM, pH 8.0; LobaChemie, Mumbai, India), thiobarbituric acid (TBA, 0.8%; LobaChemie), sodium dodecyl sulfate (SDS, 8.1%; LobaChemie), distilled water, and n-butanol (Merck, Mumbai, India)–pyridine (LobaChemie) (15:1), was centrifuged (4000 × g for 10 minutes at 4°C). The supernatant, containing pink-colored MDA-TBA adducts, was removed to measure TBARS (nM/mg protein) using the molar extinction coefficient (ε) = 1.56 × 10^5 M–1cm–1 at λ_max = 532 nm (Okawa et al., 1979). To measure GSH, the assay mixture (final volume 3 mL), containing supernatant and 4% sulfosalicylic acid (LobaChemie), was centrifuged (2000 × g for 10 minutes at 4°C), and the supernatant was combined with 5,5′-dithiobis-(2-nitrobenzoic acid) (0.1 mM, pH 8.0; LobaChemie, Mumbai, India) and phosphate buffer (0.05 M, pH 7.0), was recorded. The method described by Sastry et al. (2002) was used to calculate the total nitrite content (µM/mg of protein), using a standard curve generated using NaNO2, (concentration range: 10–100 µM). Briefly, the assay mixture, containing carbonate buffer (pH 9.0), supernatant, Cu-Cd alloy (150 mg), NaOH (0.35 M), and ZnSO4 solution (120 mM) was centrifuged (2000 × g for 10 minutes at 4°C). Supernatant was added to the Griess reagent (1:1 solution of 1% sulfanilamide in 3.0 M hydrochloric acid and 0.1% N-1-naphthylethylenediamine-2HCl in H2O), and the absorbance was recorded at λ_max = 548 nm. The total protein content was quantified using a standard curve generated using bovine serum albumin (concentration range: 0.2–2.4 mg/mL; Himedia Laboratories, Mumbai, India). The assay mixture was prepared using supernatant, Lowry’s reagent (1% w/v CuSO4 solution, 2% w/v sodium-potassium tartrate, and 2% w/v Na2CO3 in 0.1 M NaOH at a ratio of 1:1:98), phosphate buffer, and 1.0 N Folin-Ciocalteau reagent. Absorbance was recorded at λ_max = 750 nm. The protein concentration was expressed as mg/mL of homogenate (Lowry et al., 1951).

**Assays for the assessment of dopamine, DOPAC, HVA, GABA, TNF-α, and NF-κB levels**

The supernatant from the SN and ST homogenate was combined with an equivalent amount of methanol to perform protein precipitation (4°C), which was filtered using a cellulose membrane with a pore size of 0.2 µm. The supernatant (20 µL) was injected into the column (C18 column; 5 µm, 4.6 × 250 mm) of a high-performance liquid chromatography system (Waters India Pvt. Ltd., New Delhi, India) with fluorescence detection (Agilent 1260 Infinity FLD G1321C). The mobile phase consisted of acetonitrile, water, and sodium potassium phosphate buffer solution (0.01 M, pH 4.1), delivered at a flow rate of 1.2 mL/min, and the samples were separated at 27°C. The fluorescence detector was programmed at an excitation wavelength of λ_ex = 285 nm and an emission wavelength of λ_em = 333 nm. The concentrations of dopamine and its metabolites were quantified using external standards and the area under the peak technique. The peak areas were determined by injecting serial dilutions of the standards (0.5–100 ng/mL). Peak areas (vertical axis) were plotted against the corresponding concentrations (horizontal axis) of each individual monoamine standard to obtain a linear standard curve (linear regression equation for dopamine: y = 0.395x + 0.059, r² = 0.993; DOPAC: y = 0.005x + 0.163, r² = 0.998; HVA: y = 0.382x + 0.073, r² = 0.997), which was used to quantify the concentrations in samples, with detection limits 0.01–0.04 ng/mL. The eluted solution was determined using a double-beam spectrophotometer (CyberLab Analytics®, Mumbai, India) at λ_ex = 509 nm and compared against a standard curve generated using a GABA solution at concentrations ranging from 31.25 to 2000 pmol/mL (Swamy et al., 2013). A double-antibody, sandwich, enzyme-linked immunosorbent assay was used to quantify the TNF-α (Krishgen, Mumbai, India) and NF-κB levels (KinesisDX, Cerritos, CA, USA) in ST and SN structures, according to the manufacturer’s instructions. Briefly, brain tissue was homogenized as previously described and centrifuged at 2500 × g for 20 minutes. The supernatant (TNF-α, 100 µL; NF-κB, 40 µL) was separated and added to mouse monoclonal antibody pre-coated wells (12 × 8 wells). After incubation (37°C) for 1 hour, biotin-labeled detection antibody was added (TNF-α, 100 µL; NF-κB, 10 µL), followed
In agreement with previous findings (Prema et al., 2015), the bradykinesia in MPTP-treated mice was attenuated by arbutin, indicating significant improvements in the mean fall latency at various rotating speeds (5, 10, and 20 r/min) compared with those in mice treated with MPTP alone. Arbutin (50 and 100 mg/kg) administration to MPTP-mice significantly enhanced the fall latencies (5 r/min, P < 0.01; 10 and 20 r/min, P < 0.001) compared with those in mice treated with MPTP alone. The administration of arbutin (100 mg/kg) or madopar in MPTP-treated mice resulted in significantly (P < 0.001) increased fall latencies compared with those in mice treated with MPTP alone. CGS21680 administration to mice treated with MPTP and arbutin significantly attenuated the effects of arbutin on fall latency, whereas the administration of forskolin to mice treated with MPTP and arbutin potentiated the (P < 0.05) the arbutin-induced increase in fall latency compared with those in mice treated with only MPTP and arbutin (Figure 4D–F).

Arbutin reduces the oxido-nitrosative stress in the brains of MPTP-treated mice

Exposure to MPTP significantly (P < 0.001) enhanced lipid peroxidation (TBARS) (Figure 5A) and total nitrite levels (Figure 5E) and decreased GSH contents and SOD and catalase activities (Figure 5B–D) in mouse brain tissues (ST and SN) compared with those in vehicle-treated mice. However, the administration of arbutin (50 and 100 mg/kg dose) to MPTP-treated mice attenuated the TBARS (P < 0.001) and nitrite (P < 0.05, P < 0.01) levels, increased the GSH levels (P < 0.05, P < 0.001) and SOD (P < 0.05, P < 0.01) and catalase (P < 0.05, P < 0.01) activities compared with those in mice treated with MPTP alone. Madopar administration to MPTP-treated mice decreased the TBARS (P < 0.001) and nitrite (P < 0.01) contents and increased the GSH contents (P < 0.01) and SOD (P < 0.01) and catalase (P < 0.01) activities compared with those in mice treated with MPTP alone. Interestingly, the administration of CGS21680 to mice treated with MPTP and arbutin significantly enhanced the TBARS (P < 0.001) and nitrite (P < 0.05) levels and reduced (P < 0.05) the levels and activities of the antioxidants (GSH, SOD, and catalase) in the

Arbutin ameliorates the locomotor and exploratory activities of MPTP-treated mice

OFT is used to assess locomotor and exploratory activities, which are key parameters of anxiety in rodents. Therefore, reduced OFT performances correlate with increased levels of anxiety in rodents. The administration of MPTP to mice caused a significant decline in OFT performance compared with vehicle-treated mice, which was demonstrated by a considerable decrease (P < 0.001) in the numbers of lines crossed, squares crossed, rearing events, and grooming behaviors. In the present study, the administration of arbutin (50 and 100 mg/kg) or madopar to MPTP-treated mice resulted in considerable improvements (P < 0.001) in OFT performances compared with those of mice treated with MPTP alone. The administration of CGS21680 (A2AR agonist) in mice treated with MPTP and arbutin 1 hour prior to OFT assessment substantially (P < 0.05) attenuated the arbutin-induced improvements in OFT performance compared with that of mice treated with only MPTP and arbutin. In contrast, the administration of forskolin (adenylyl cyclase agonist) to mice treated with both MPTP and arbutin significantly potentiated the arbutin-mediated increase in the numbers of lines (P < 0.05), squares crossed, rearing events, and grooming behaviors (P < 0.01) compared with mice treated with only MPTP and arbutin (Figure 3).

Arbutin attenuates the symptoms of akinesia and bradykinesia in MPTP-treated mice

In agreement with previous findings (Prema et al., 2015), the administration of MPTP caused akinesia and bradykinesia in mice, as measured using the catalepsy test and pole test, respectively, compared with mice treated with vehicle, as indicated by a significant increase (P < 0.001) in the cataleptic score (Figure 4A) and in the t-turn (Figure 4B) and t-total times recorded in the pole-test (Figure 4C). The administration of arbutin (50 and 100 mg/kg) or madopar to 7 days to MPTP-treated mice substantially (P < 0.001) cataleptic behavior compared with that in mice treated with MPTP alone. Arbutin (50 and 100 mg/kg) administration to MPTP-treated mice significantly decreased the t-turn (P < 0.01 and P < 0.001, respectively) and t-total (P < 0.01 and P < 0.001, respectively) times compared with mice treated with MPTP alone. The administration of madopar to MPTP-treated mice also decreased the t-turn (P < 0.001) and t-total (P < 0.01) times compared with those in mice treated with MPTP alone. However, the administration of CGS21680 to mice treated with MPTP and arbutin abolished the arbutin-induced improvements in akinesia (P < 0.01) and bradykinesia (P < 0.05) compared with those in mice treated with only MPTP and arbutin. The administration of forskolin to mice treated with MPTP and arbutin resulted in the synergistic enhancement of the arbutin-induced decreases in the cataleptic score (P < 0.01) and t-turn (P < 0.01) and t-total (P < 0.01) times compared with mice treated with only MPTP and arbutin.
ST and SN regions compared with those in mice treated with only MPTP and arbutin. The administration of forskolin to mice treated with MPTP and arbutin reduced TBARS levels (P < 0.001) and enhanced the GSH levels (P < 0.001) and SOD (P < 0.01) and catalase (P < 0.001) activities in the ST and SN compared with mice treated with only MPTP and arbutin. The results of this study indicated that arbutin was able to restrain oxido-nitrosative stress in brain regions associated with PD pathogenesis (Figure 5A–E). Furthermore, the activation of A1R by GS21680 inhibited the antioxidative effects of arbutin, whereas the increase in cAMP associated with forskolin administration markedly potentiated the effects of arbutin.

Arbutin improves the dopamine, DOPAC, HVA, and GABA levels in the brains of MPTP-treated mice

PD is characterized by significant decreases in dopaminergic (Hartmann, 2004) and GABAergic signaling in the basal ganglia (Swamy et al., 2013; Prema et al., 2015). In the present study, MPTP treatment decreased (P < 0.001) the levels of dopamine, DOPAC, HVA, and GABA in the examined brain regions (ST and SN) of mice when compared with those in mice treated with vehicle. The administration of arbutin (50 and 100 mg/kg) in MPTP-treated mice enhanced the levels of dopamine (P < 0.05, P < 0.01), its metabolites (P < 0.01, P < 0.001), and GABA (P < 0.01, P < 0.001) compared with those in mice treated with MPTP alone. Madopar administration
to MPTP-treated mice also improved the dopamine (P < 0.01), DOPAC (P < 0.05), HVA (P < 0.01), and GABA (P < 0.05) levels in the ST and SN compared with those in mice treated with MPTP alone. The administration of CGS21680 to mice treated with both MPTP and arbutin significantly inhibited the arbutin-induced increase in dopamine (P < 0.05), DOPAC (P < 0.01), HVA (P < 0.01), and GABA (P < 0.05) levels in the ST and SN compared with mice treated with only MPTP and arbutin. Forskolin administration in mice treated with MPTP and arbutin increased the dopamine (P < 0.001), DOPAC (P < 0.01), HVA (P < 0.001), and GABA (P < 0.01) levels in the ST and SN compared with those in mice treated with only MPTP and arbutin. Therefore, arbutin appeared to enhance dopaminergic and GABAergic signaling in the brain, despite MPTP treatment, which could be decreased by CGS21680 and potentiated by forskolin (Figure 6).

Arbutin attenuates neuroinflammation in MPTP-treated mice

MPTP treatment resulted in a substantial increase (P < 0.001) in the TNF-α and NF-κB levels in the examined brain regions (ST and SN) of mice compared with those in mice treated with vehicle. The administration of arbutin (50 and 100 mg/kg) to mice treated with MPTP significantly attenuated the MPTP-induced increase in TNF-α (P < 0.01) and NF-κB levels (P < 0.05, P < 0.001) compared with those in mice treated with MPTP alone. Madopar administration to MPTP-treated mice significantly attenuated the MPTP-induced increase in TNF-α (P < 0.05) and NF-κB levels (P < 0.01) compared with those in mice treated with MPTP alone. The administration of CGS21680 to mice treated with MPTP and arbutin enhanced the TNF-α and NF-κB levels (P < 0.05) in the ST and SN compared with those in mice treated with only MPTP and arbutin. Forskolin administration in mice treated with MPTP and arbutin decreased the TNF-α (P < 0.01) and NF-κB levels (P < 0.05) compared with those in mice treated with only MPTP and arbutin (Figure 7).

Figure 6  |  Arbutin (50 and 100 mg/kg) enhances the levels of neurotransmitters in the striatum and substantia nigra brain structures of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.

Mice were injected with MPTP (30 mg/kg) from days 1 to 4 to induce Parkinson’s disease symptoms. Mice were also treated concurrently with arbutin or madopar for 7 days, with injections occurring 30 minutes after MPTP treatment. CGS21680 (0.5 mg/kg) and forskolin (3 mg/kg) were injected 1 hour before behavioral studies were performed in MPTP and arbutin-treated mice. Normal saline (vehicle control) and arbutin (50 mg/kg) were administered in separate groups of mice for 7 days. (A–D) Quantitative results showing levodopa (A), 3,4-dihydroxyphenylacetic acid (DOPAC) level (B), homovanillic acid (HVA) (C), and γ-aminobutyric acid (GABA) (D) measured after behavioral studies on day 7. All values are presented as the mean ± SEM (n = 6). Data were analyzed by one-way analysis of variance, followed by Tukey’s honestly significant difference post hoc test: **P < 0.01, vs. vehicle-control group. *P < 0.05, **P < 0.01, ***P < 0.001, vs. MPTP group; #P < 0.05, ##P < 0.01, ###P < 0.001, vs. MPTP + Arbutin50 group. TBARS: F(7,40) = 67.73, P < 0.001; GSH: F(7,40) = 41.62, P < 0.001; SOD: F(7,40) = 26.93, P < 0.001; CAT: F(7,40) = 74.58, P < 0.001; nitrite: F(7,40) = 56.73, P < 0.001.

Figure 7  |  Arbutin (50 and 100 mg/kg) reduces the levels of oxido-nitrosative stress in the striatum and substantia nigra regions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.

Mice were injected with MPTP (30 mg/kg) from days 1 to 4 to induce Parkinson’s disease symptoms. Mice were also treated concurrently with arbutin or madopar for 7 days, with injections occurring 30 minutes after MPTP treatment. CGS21680 (0.5 mg/kg) and forskolin (3 mg/kg) were injected 1 hour before behavioral studies were performed in MPTP and arbutin-treated mice. Normal saline (vehicle control) and arbutin (50 mg/kg) were administered in separate groups of mice for 7 days. (A–E) Quantitative results showing thiobarbituric acid reactive substances (TBARS) contents (A), glutathione (GSH) levels (B), superoxide dismutase (SOD) activity (C), catalase activity (D), and total nitrite contents (E) measured after behavioral studies on day 7. All values are presented as the mean ± SEM (n = 6). Data were analyzed by one-way analysis of variance, followed by Tukey’s honestly significant difference post hoc test: **P < 0.01, vs. vehicle-control group; *P < 0.05, **P < 0.01, ***P < 0.001, vs. MPTP group; #P < 0.05, ##P < 0.01, ###P < 0.001, vs. MPTP + Arbutin50 group. TBARS: F(7,40) = 67.73, P < 0.001; GSH: F(7,40) = 41.62, P < 0.001; SOD: F(7,40) = 26.93, P < 0.001; CAT: F(7,40) = 74.58, P < 0.001; nitrite: F(7,40) = 56.73, P < 0.001.
histopathology analysis. Mice treated with vehicle or arbutin alone showed no signs of neurodegeneration, with normal brain tissue architecture (Figure 8A and B). The administration of MPTP caused neurodegenerative changes in the ST, which were characterized by the blebbing of the plasma membrane and chromatin condensation (Figure 8C). The administration of arbutin or madopar to MPTP-treated mice significantly attenuated the MPTP-induced neurodegenerative changes in the ST (Figure 8D–F). The administration of CGS21680 to mice treated with MPTP and arbutin attenuated neuroprotective effects of arbutin, whereas forskolin administration synergized these effects (Figure 8G and H).

Discussion
The mutual inhibitory signaling between A2ARs and dopamine receptors adversely affects the motor circuit and acts on both direct (monosynaptic GABA-regulated inhibitory pathway) and indirect (polysynaptic excitatory) pathways in the basal ganglia (Cieslak et al., 2008). The antagonistic A2A-R-D1/D2 receptor heterodimeric complex in the basal ganglia has been shown to inhibit D1-mediated inhibitory GABAergic transmission (resulting in an excitatory effect on the direct pathway) or to activate the D2-mediated indirect pathway (resulting in an inhibitory effect). The subsequent loss of inhibitory control over thalamocortical projection neurons results in motor dysfunctions (Kulisevsky and Poyurovsky, 2012) and the excitotoxic degeneration of dopaminergic neurons (Saransaari et al., 2013). Existing evidence suggests that the in vivo generation of MPP+ from MPTP by MAO-B causes the selective degeneration of dopaminergic nigrostriatal neurons (Huang et al., 2017). Decreased dopamine levels enhance the inhibitory influence of A2ARs on the existing dopamine nigrostriatal receptors, which aggravates the typical PD symptoms (Mori and Shindou, 2003). Furthermore, pre-clinical studies reported improved locomotor activity following the administration of A2A antagonists (e.g., KW 6002), further supporting the ability to use the MPTP model to screen putative anti-PD drugs that may act via A2ARs (Shiozaki et al., 1999; Cieslak et al., 2008). The prevention of excitotoxic signaling and the inhibition of the AMPK-autophagy pathway associated with arbutin treatment suggests that arbutin may be able to provide PD symptom relief and indicates the potential role played by A2A-Rs in PD pathology (Ahmadian et al., 2019; Ding et al., 2020). Several studies have suggested that arbutin can modulate brain functions (Dadgar et al., 2018). Hydroquinone (Ha Park et al., 2016) and its derivatives, including arbutin, can penetrate through biological barriers, such as the plasma membrane (Gallo et al., 2015) and the blood-brain barrier, when administered either orally or systemically. The present findings indicated that arbutin protected dopaminergic nigrostriatal neurons and attenuated the MPTP-induced PD-like symptoms in mice (e.g., akinesia, bradykinesia, loss of motor coordination, postural imbalance, and reduced muscle strength). Interestingly, we observed that the activation of A2A Rs by CGS21680 attenuated the anti-PD activities of arbutin in the MPTP model, whereas the activation of adenylyl cyclase-cAMP by forskolin enhanced these effects. MPTP treatment induces mitochondrial dysfunction, particularly at complex I of the electron transfer chain,
which causes energy failure and the generation of highly reactive species (e.g., oxygen, nitrite radicals, and aldehydes) (Huang et al., 2017), which can have deleterious effects on nigrostriatal dopaminergic neurons (Dauer and Przedborski, 2003). MDA, 4-hydroxy-2-nonenal, and isoprostanes are highly immunogenic, lipid-peroxidizing, neurotoxic aldehydes that form complex bimolecular aggregates, deplete endogenous antioxidants, and disrupt neuronal membrane integrity (Guo et al., 2018). In the present study, the administration of MPTP considerably enhanced oxi-do-nitrosative stress in the brains (SN and ST) of mice. MPTP increased lipid peroxidation (TBARS) and nitrite levels and decreased the levels and activities of endogenous antioxidants, such as GSH, SOD, and catalase. The MPTP-induced increase in oxidative stress was effectively abolished, and the endogenous antioxidant levels were enhanced by the administration of arbutin (50 and 100 mg/kg) in MPTP-treated mice. The antioxidant effects demonstrated by arbutin (100 mg/kg) were similar to those of the standard PD-treatment drug (madopar) used in this study. The presence of five hydroxyl (–OH) groups in arbutin confers a robust free radical scavenging property. The classical structure-activity relationship theory directly correlates the number of oxidizable –OH groups in a molecule with its free radical scavenging efficacy. In previous studies, arbutin showed excellent 2,2-diphenyl-1-picrylhydrazyl and 2,2’-azinobis(3-ethylbenzothiazoline-6-sulphonic acid) radical scavenging activities because one molecule of arbutin can quench five radicals (Takebayashi et al., 2010). Recently reported data have reported that A2AR antagonists (e.g., SCH-58261, ZM-241385, KD-64, caffeine) protect against reactive oxygen species, nitric oxide synthase, cyclo-oxygenase, and microglia-mediated inflammation (Paterniti et al., 2011; Borea et al., 2018; Colella et al., 2018; Aires et al., 2019; Kotasinska et al., 2020). A substantial increase in the expression of A2ARs in the basal ganglia neurons (Varani et al., 2010), commensurate with the detection of chronic oxidative stress and inflammation, has been observed in response to noxious stimuli, such as MPTP or 6-hydroxydopamine (Schwarzchild et al., 2006; Shen and Chen, 2009). The activation of A2ARs antagonizes the D2 receptor-mediated suppression of Ca2+ influx through L-type voltage-dependent Ca2+ channels (Shen and Chen, 2009). Excess intracellular Ca2+ in the basal ganglia triggers the release of stored Ca2+ from the endoplasmic reticulum, resulting in mitochondrial Ca2+ overload, which triggers the opening of the mitochondrial membrane permeability transition pore, the release of cytochrome c, and the activation of apoptotic cell death pathways (Görlach et al., 2015). In agreement with these earlier findings, the administration of CGS21680 (A2Rs agonist) one hour before behavioral studies in this study antagonized the antioxidative effects of arbutin, whereas the administration of forskolin (adenylyl cyclase agonist) potentiated the effects of arbutin in MPTP-treated mice. The literature reports have indicated that the activation of A2ARs by CGS21680 enhances the production of free oxygen and nitrogen radicals in brain tissues (Saura et al., 2005), whereas the activation of adenylyl cyclase by forskolin reduces these oxidative effects (Mehan et al., 2017). Free radicals and associated events (e.g., peroxidation of biomolecules, formation of neurotoxic aldehydes) activate the NF-kB-mediated transcription of pro-inflammatory cytokines (e.g., TNF-α, interleukins, nitric oxide synthase, and cyclo-oxygenase-2) in the striatum (Yan et al., 2014). Evidence has suggested that during the early prodromal phase of PD, the NF-kB-triggered inflammation initiates the retrograde degeneration of nigral dopaminergic neurons (Bellucci et al., 2020). The increased expression of pro-inflammatory cytokines, microglial activation, and the extravasation of T-cells (CD8+ and CD4+) in the SN are consistent with PD pathogenesis (Tufekci et al., 2012; Zaitone et al., 2012). TNF-α activates pathways that trigger apoptosis and necrotic cell death (via caspases and p53), resulting in the gradual loss of dopaminergic innervations from the SN pars compacta to the ST. In the present study, MPTP significantly enhanced the TNF-α and NF-kB levels in the brains of mice. These findings support the findings of earlier studies, which showed the MPTP-induced activation of NF-kB, nitric oxide synthase, cyclo-oxygenase-2, and microglia (Khan et al., 2013) and the increased expression of pro-inflammatory cytokines and pro-apoptotic factors (e.g., Bax and Bad) in the SN and ST regions of mice (Meredith and Rademacher, 2011). However, the administration of arbutin (50 and 100 mg/kg) or madopar in MPTP-treated mice for 7 days decreased the TNF-α- and NF-kB-mediated inflammation. CGS21680 abolished the anti-inflammatory activities of arbutin in MPTP-treated mice, whereas forskolin synergized these effects. The neuroprotective activity of arbutin was supported by histopathology studies. MPTP treatment caused the marked neurodegeneration of the ST regions in the brains of mice, which could be prevented by treatment with arbutin. CGS21680 attenuated the neuroprotective effects of arbutin in MPTP-treated mice, whereas forskolin enhanced these effects.

The levels of dopamine, its metabolites (e.g., DOPAC and HVA), and GABA were also evaluated in the SN and ST brain regions to assess the effects of arbutin on dopaminergic and GABAergic transmissions in MPTP-treated mice. In PD, the A2AR-mediated decrease in D2 receptor activation downregulates GABAergic inhibitory neurotransmission in the globus pallidus and SN, which triggers motor symptoms, such as gait abnormality, postural imbalance, rigidity, and tremors (Kulisevsky and Poyurovsky, 2012). The appearance of non-motor symptoms in PD has been attributed to a decrease in the GABA contents of the brain (Blaszczyk, 2016). In the current research, the administration of MPTP caused a significant decline in the dopamine, DOPAC, HVA, and GABA levels in the SN and ST regions. MPTP has also been shown to decrease dopaminergic and GABAergic signaling in the basal ganglia. In several previous studies, an increase in locomotor function following treatment with A2AR antagonists suggested control over MPTP-mediated dopaminergic loss (Shen and Chen, 2009). In the present study, the administration of arbutin or madopar to MPTP-treated mice significantly elevated the dopamine, DOPAC, HVA, and GABA levels compared with untreated mice treated with MPTP alone. The antioxidative and anti-inflammatory activities of arbutin (Damer et al., 2018) might also result in the reduction of dopaminergic neurons against MPTP toxicity. Subsequently, GABA activity is enhanced due to the dopamine receptor-mediated increase in the firing rate of GABAergic neurons in the striatum (Schwarzchild et al., 2006). However, CGS21680 decreased the arbutin-induced increases in dopamine, DOPAC, HVA, and GABA levels in MPTP-treated mice, whereas forskolin treatment further enhanced these levels. Previous findings also indicate that A2AR transmission can inhibit dopaminergic and GABAergic signaling (Saransaari and Oja, 2005; Cieślak et al., 2008).

The biochemical findings supported the results of the behavioral studies. MPTP caused a significant increase in PD-like motor symptoms in mice, including the decreased performance in the OFT and reduced muscle strength and motor coordination, as measured by the rotarod test. MPTP triggered akinnesia and bradykinesia in mice, as demonstrated by the increased cataleptic score and the t-turn and t-total times. The MPTP-induced motor dysfunction was effectively attenuated by treatment with arbutin (50 and 100 mg/kg). As expected, madopar also attenuated the MPTP-induced motor deficits in mice. However, CGS21680 antagonized the activities of arbutin, whereas forskolin potentiated the effects of arbutin in MPTP-treated mice. Although the A2AR-cAMP pathway is involved in a wide range of physiological activities (Peleli et al., 2018), in this study, the activation of A2ARs was found...
to aggravate the MPTP-induced PD-like pathology in mice, whereas forskolin (adenyl cyclase-cAMP agonist) potentiated the anti-PD effects of arbutin. Although A<sub>2A</sub>R activation typically increases the activity of the adenylyl cyclase-cAMP pathway, D2 receptors typically inhibit this pathway (Shen and Chen, 2009); however, in the present study, increased adenylyl cyclase-cAMP activity attenuated motor dysfunction, which indicated a differential role for cAMP in the pathogenesis of PD. Although the absorption of arbutin from the gastrointestinal tract is excellent, the potential generation of D-glucose and hydroquinone by intestinal microflora under aerobic conditions may limit the drug’s activity when it is administered orally. The systemic administration of arbutin avoids the potential for free hydroquinone production, with fewer side effects compared with oral administration (Schindler et al., 2002; de Arriba et al., 2013).

Data obtained from human studies have revealed that in addition to the loss of dopaminergic neurons in the SN, other neuronal types (e.g., adrenergic, cholinergic, glutamatergic, serotonergic, and GABAergic) are also adversely affected by the progression of PD (Hartmann, 2004). Significant increases in the levels of oxidative stress biomarkers (e.g., 8-hydroxyguanosine, carbonyl, 4-hydroxy-2-nonenal, and MDA) and inflammatory markers (e.g., TNF-α, interleukin 1β, interleukin 6, and interferon γ) and decreased GSH-dependent antioxidants in the SN region and cerebrospinal fluid have consistently been observed in PD patients (Faroqui and Farooqui, 2011). These findings indicated that oxidative and inflammatory insults are the primary factors that contribute to the degeneration of dopaminergic neurons and the formation of toxic protein aggregates in the brain. Abnormalities in the ubiquitin-proteasome and autophagy-lysosome pathways may hamper the removal of misfolded proteins, such as α-synuclein, from the brain (Toulorge et al., 2016). In this study, arbutin ameliorated the motor functions in MPTP-treated mice by protecting dopaminergic neurons against oxido-nitrosative and inflammatory damage, in addition to restoring the levels of dopamine and GABA transmitters in the striatum. The therapeutic benefits of arbutin in the MPTP model can be extended to the other models of PD as several studies have reported that chronic exposure to chemicals such as MPTP, rotenone (a pesticide), paraquat (herbicide), and maneb (fungicide) can initiate a vicious cycle of self-replenishing neurotoxins (e.g., free radicals, lipid peroxidation products, and pro-inflammatory cytokines) that specifically decrease the dopaminergic neuron density in the striatum (Sherer et al., 2003; Meredith et al., 2008; Prema et al., 2015) and initiate Lewy body pathology (Jagmag et al., 2015). Therefore, the findings of the present study revealed that arbutin targeted multiple neurotoxic events that suggest that arbutin may be suitable as an anti-PD drug, with the potential to enhance therapeutic outcomes in PD patients. Arbutin has been reported to modulate PD drug; however, additional investigations (e.g., receptor-binding studies) remain necessary to correlate these relationships. Furthermore, the present study indicated that A2AR activation and the adenylyl cyclase-cAMP pathways might be involved in the mitigation of PD-like symptoms following arbutin treatment in the MPTP mouse model. However, additional studies (e.g., radioligand binding assays) remain necessary to elucidate the anti-PD mechanism of arbutin and the involvement of adenosine receptors.

In this study, the anti-PD effects observed in the MPTP mouse model can be attributed to the protective effects of arbutin on the existing neurons. The extent of neurodegeneration tends to be high by the time that clinical symptoms manifest in PD patients. However, the present results suggest that the therapeutic effects of arbutin might be correlated with the upregulation of dopamine and GABA levels, in addition to antioxidant and anti-inflammatory effects in the ST and SN regions of the brain. Arbutin treatment might be able to rescue neuronal viability before irreversible damage occurs in the basal ganglia. The findings of the present study favor the pro-survival and regenerative capabilities of arbutin, which will be evaluated in future studies. In this study, CGS21680 and forskolin were used as pharmacological interventions to explore the influence of A<sub>2A</sub>Rs and cAMP on the effects of arbutin on PD symptoms. Interestingly, we observed the involvement of A<sub>2A</sub>R-cAMP in the anti-PD effects of arbutin in the MPTP mouse model. However, further studies are required to establish the direct associations between the A<sub>2A</sub>R-cAMP pathway and the therapeutic effects of arbutin against PD.

In summary, arbutin improved various motor functions, including posture, movement, and rigidity in MPTP-treated mice. Arbutin exhibited potent antioxidant and anti-inflammatory activities and was able to restore the neurotransmitter levels (e.g., dopamine and GABA) in the striatum and protect neurons against degeneration. The findings of this study indicated that the inhibition of A<sub>2A</sub>Rs and increased adenylyl cyclase-cAMP activity in the brain might be involved in the observed therapeutic benefits associated with arbutin treatment in the MPTP model of PD. Arbutin can be used as an alternative or co-adjuvant drug in the therapy of PD.

Acknowledgments: The authors are thankful to the management of Swift School of Pharmacy, Ghoggar Sarai (Rajpura) for providing the necessary research facilities.

Author contributions: Study conception and design: MK, ZY; literature search: JZ, JS; experiment implementation: JS; data analysis: MK, JZ; manuscript draft: MK. All authors read and approved the manuscript.

Conflicts of interest: None declared.

Financial support: None.

Institutional review board statement: The study protocol was approved by the Institutional Animal Ethics Committee (1616/PO/Re/S/12/CPCSEA) on November 17, 2019 with approval No. IAEC/2019/010. All the animal experimentation was performed as per instructions of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India, New Delhi.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Data sharing statement: Datasets analyzed during the current study are available from the corresponding author on reasonable request.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References
Abloovich A, Gillor AD (2016) Defects in trafficking bridge Parkinson’s disease pathology and genetics. Nature 539:207-216.
Ahnadian SR, Ghasemifar-Kasman M, Pouramin M, Sadeghi F (2019) Arbutin attenuates cognitive impairment and inflammatory reaction in a rat model of 6-hydroxydopamine-induced kindling model of epilepsy. Neuropharmacology 146:117-127.
Aires ID, Boia R, Rodrigues-Neves AC, Vadehra MD, Marques C, Ambrosio AF, Santiago AR (2019) Blockade of microglial adenosine A2A receptor suppresses elevated pressure-induced inflammation, oxidative stress, and cell death in retinal cells. Glia 67:896-914.
